FDA grants priority review to Genentech’s Rituxan (rituximab) in children with two rare blood vessel disorders


12 June 2019 - If approved, this would be the first paediatric indication for Rituxan.

Genentech announced today that the U.S. FDA has accepted the company’s supplemental biologics license application and granted priority review for the use of Rituxan (rituximab), in combination with glucocorticoids (GCC), for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children two years of age and older. GPA and MPA are rare, potentially life-threatening diseases affecting small and medium sized blood vessels.

The application was submitted based on data from the PePRS study, a Phase IIa, global, open-label, single-arm study investigating the safety, pharmacodynamics/pharmacokinetics and exploratory efficacy of intravenous Rituxan in 25 patients with severe GPA or MPA between six and 17 years of age.

Read Genentech press release

Michael Wonder

Posted by:

Michael Wonder